No Data
No Data
Eli Lilly's GLP-1 Impact on ResMed Is Overblown: Barron's
GLP-1 Concerns Clobbered This Healthcare Stock. Now It's Time to Buy.
ResMed makes its bank from products that battle sleep apnea. When that business seemed threatened, investors fled. Now it looks like they were too hasty. By Jacob Sonenshine ResMed is the latest
Express News | Resmed Inc : BofA Global Research Raises Price Objective to $230 From $225
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $230
BofA Securities analyst Lyanne Harrison maintains $ResMed(RMD.US)$ with a buy rating, and adjusts the target price from $225 to $230.According to TipRanks data, the analyst has a success rate of 45.5%
Resmed Poised for Growth: Strong U.S. Device Sales and SaaS Segment to Drive Performance Despite Industry Challenges
Here's Why ResMed (RMD) Is a Strong Growth Stock
No Data
CyborgJack : tell us something we don't know! I can ask chatgpt for what you just told me lol.
Kevin TraversOP CyborgJack: do it then
Paul bin Anthony :
Kevin TraversOP Paul bin Anthony: WOAH HOLY CRUD
Rusty Shackleford 1 Kevin TraversOP: You didn't notice it says practice
View more comments...